Study to know the effects of using a chemotherapy drug named pazopanib in advanced soft tissue cancer at a cancer center
Not Applicable
Completed
- Conditions
- Health Condition 1: C499- Malignant neoplasm of connective and soft tissue, unspecifiedHealth Condition 2: null- Pathologically confirmed soft tissue sarcoma patient who were treated with pazopanib based therapy during the study period
- Registration Number
- CTRI/2018/01/011112
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 21
Inclusion Criteria
1.Pathologically confirmed STS patient who were treated with pazopanib based therapy during the study period.
2.Availability of adequate clinico-pathological, treatment related details and follow-up records in EMR or case records of the patients.
Exclusion Criteria
1.Patients who do not meet the above criteria.
2.Patients who has taken treatment for less than 3 months.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess <br/ ><br>1.Response rates <br/ ><br>2.Progression free survival <br/ ><br>3.Grade III/IV toxicity (hematological and non-hematological) <br/ ><br>Timepoint: 2 and 5 years
- Secondary Outcome Measures
Name Time Method Overall survivalTimepoint: 2 and 5 years